Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Moleculin Biotech ( (MBRX) ).
On September 25, 2025, Moleculin Biotech announced that the Canadian Intellectual Property Office has issued a notice of allowance for a patent application related to Annamycin, a drug candidate for treating hard-to-treat cancers. The patent, expected to be issued soon, will cover methods of creating a preliposomal Annamycin lyophilizate with improved stability and purity, extending its base patent term until June 2040. This development strengthens Moleculin’s intellectual property portfolio and supports its efforts to advance Annamycin as a transformative therapeutic candidate.
The most recent analyst rating on (MBRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is a next-generation anthracycline designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, avoiding common cardiotoxicity and multidrug resistance.
Average Trading Volume: 5,996,284
Technical Sentiment Signal: Sell
Current Market Cap: $21.07M
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.